These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6672998)

  • 1. [Fibrinolytic and defibrinogenation therapy].
    Mannucci PM; Mari D
    Ric Clin Lab; 1983; 13 Suppl 3():245-55. PubMed ID: 6672998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
    Kwaan HC
    Thromb Diath Haemorrh Suppl; 1973; 56():239-51. PubMed ID: 4617331
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hemodilution, defibrinogenation and plasmapheresis in hemorheology].
    Bartolo M
    Ric Clin Lab; 1985; 15 Suppl 1():439-54. PubMed ID: 4035226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic defibrinogenation as conservative therapy of peripheral arterial occlusive disease. A critical analysis].
    Ernst E
    MMW Munch Med Wochenschr; 1983 Sep; 125(37):796-8. PubMed ID: 6415441
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood viscosity and thrombosis: clinical considerations.
    Smith BD; La Celle PL
    Prog Hemost Thromb; 1982; 6():179-201. PubMed ID: 6762612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
    Lowe GD; Morrice JJ; Fulton A; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1978 Aug; 40(1):134-43. PubMed ID: 725844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
    Urano T; Ihara H; Takada Y; Fujie M; Takada A
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
    J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between autonomic function and plasma fibrinogen, viscosity, and elements of fibrinolytic activity in diabetic nephropathy.
    Weinrauch LA; Gleason RE; Keough J; D'Elia JA
    Am J Hypertens; 1997 Apr; 10(4 Pt 1):454-61. PubMed ID: 9128213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings: Clinical improvement in peripheral circulation by controlled defibrinogenation.
    Dormandy JA; Goyle KB
    Br J Surg; 1976 Aug; 63(8):661-2. PubMed ID: 953495
    [No Abstract]   [Full Text] [Related]  

  • 16. Ancrod.
    Sherman DG
    Curr Med Res Opin; 2002; 18 Suppl 2():s48-52. PubMed ID: 12365829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood and plasma viscosity in experimentally induced hyper- and hypo-fibrinogenaemia.
    Pola P; Flore R; Tondi P
    Int J Tissue React; 1986; 8(4):333-6. PubMed ID: 2943690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes--a multicentre trial.
    Latallo ZS
    Thromb Haemost; 1983 Aug; 50(2):604-9. PubMed ID: 6227104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.